Dato Dr Kim Tan
Chairman of SpringHill Management, a private fund management company specialising in biotech and social venture capital investments. He is a partner of a number of impact funds including Inqo Investments (SA), Novastar Ventures (Kenya), Springhill Equity Partners (US) and Garden Impact Investment (Singapore). He is the co-founder of the Transformational Business Network and is a trustee of the John Templeton Foundation, Templeton Religion Trust and the Centre for Enterprise, Markets & Ethics (Oxford), and an advisor to Johnson & Johnson Impact Ventures. He was the founder chairman of the NCI Cancer Hospital (Malaysia), and former board member of the Saracens Rugby Club (UK) and the APEC Life Science Innovation Forum. He is a Pro-Chancellor of the University of Surrey (UK), the inventor of sheep monoclonal antibodies and a Fellow of the Royal Society of Medicine (UK).